title: [Anti-angiogenic strategy: therapy optimization of non-squamous non-small cell lung carcinoma].
abstract: Anti-angiogenic treatment with anti-VEGF compounds plays a central role in the therapy of non-squamous non-small cell lung cancer (NSCLC). However, biometric analysis of overall survival of the established treatment options reveals several limitations of efficacy in unselected patient cohorts. Furthermore, there are no established predictive biomarkers to help select patients who might benefit from this treatment option. This review focuses on underlying principles of action of tumor-related angiogenesis and presents new treatment options that may contribute to improved overall survival.
authors.affiliation: LungenClinic, Onkologischer Schwerpunkt, Großhansdorf; Mitglied des Deutschen Zentrums für Lungenforschung (DZL).
authors.forename: N
authors.initials: N
authors.lastname: Reinmuth
authors.affiliation: LungenClinic, Onkologischer Schwerpunkt, Großhansdorf; Mitglied des Deutschen Zentrums für Lungenforschung (DZL).
authors.forename: M
authors.initials: M
authors.lastname: Reck
authors.affiliation: Ev. Lungenklinik Berlin, Klinik für Pneumologie.
authors.forename: C
authors.initials: C
authors.lastname: Grohé
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D015984:Causality; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D018579:Patient Selection; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors